CLRB Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Cellectar Biosciences Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCLRB

Market Cap24.4M

Cash RunwayRunway < 6 months

Next Catalyst2028-02

Public Research Snapshot

Cellectar Biosciences Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for NOV-205 in Hepatitis C (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Related Documents	Presentation at ASCO 2026	n/a	n/a	Public pipeline row
NOV-205	Hepatitis C	n/a	Phase 2	Public pipeline row
I124-NM404	Non Small Cell Lung Cancer	n/a	Phase 1	Public pipeline row
I-124-CLR1404	Glioblastoma	n/a	Phase 2	Public pipeline row
Iopofosine I 131	Breast Cancer	n/a	Phase 1	Public pipeline row
I-131-CLR1404 Injection	Glioma	n/a	Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2028-02	Iopofosine I 131	Low
Corporate Update	Timing not specified	n/a	Low
Data Readout	Timing not specified	n/a	Low
Presentation	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01058512	Phase 2	COMPLETED	22	2010-12
NCT01778088	Phase 2	WITHDRAWN	n/a	2014-06
NCT00582283	Phase 1	COMPLETED	21	2014-08-01
NCT01898273	Phase 2	TERMINATED	7	2015-09
NCT07311993	Phase 1	RECRUITING	60	2028-02

Scientific Context

catalyst_type | Corporate Update
catalyst_type | Data Readout
catalyst_type | Presentation
asset_name | I-124-CLR1404
clinical_stage | Phase 2

Want the full CLRB research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.